

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

ATTORNEY DOCKET NO. GG119.2US	APPLICATION NO. Unassigned
APPLICANT Carl Risinger et al.	
FILING DATE August 30, 2001	GROUP Unassigned

11040 U.S. PT  
09/943531  
08/30/01

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
46	AA	5,912,120	15-Jun-1999	Goldstein et al.	435	6	
46	AB	5,786,191	28-Jul-1998	Goldstein et al.	435	189	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

EXPRESS MAIL NO. EK748827470US


## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
46	AI	WO 00/12757	25-Aug-1999	Hauzenberger	C12Q	1/68	
	AJ						
	AK						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	
AM	
AN	
AO	
AP	

EXAMINER <i>Smits</i>	DATE CONSIDERED 9/22/05
--------------------------	----------------------------



Form PTO/SB/08 (2-92)

 INFORMATION DISCLOSURE CITATION  
 IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 532592002000

Application Number 09/943,531

Applicant

Carl RISINGER, et al.

Filing Date August 30, 2001

Group Art Unit 1635

Mailing Date August 25, 2003

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
DUPPLIC.	1.	07/1998	5,786,191	Goldstein, et al.	435	189	DUPPLICATE
DUPPLIC.	2.	06/1999	5,912,120	Goldstein, et al.	435	6	DUPPLICATE

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
HP	3.	11/1995	WO 95/30766	PCT			
HP	4.	03/2000	WO 00/12757	PCT			
HP	5.	07/2002	PCT/GB01/00828	GB			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
HP	6.	Database EMBL "Online! retrieved from EMBL, Accession no.AR071577 (Abstract)
HP	7.	Excoffier, et al. (1995) Mol Biol Evol 12:921-927
HP	8.	Karam, W.G. et.al. (1996) Drug Metabolism and Disposition 24(10):1081-1087
HP	9.	Kim, M.J. et al. (2001) Clinical Pharmacology & Therapeutics 69(2):P39
HP	10.	http://www.imm.ki.se/cypalleles/for listing (printed 08/18/03)

EXAMINER:

DATE CONSIDERED:

9/22/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Sheet 1 of 3

Attorney Docket No: SGL-2020-UT

**US PATENT DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	4,656,127	04/07/1987	MUNDY	DUPLICATE IDS
	A2.	4,683,195	07/28/1987	MULLIS and ERLICH	NOT CONSIDERED
	A3.	4,683,202	07/28/1987	MULLIS	see 8/10/05 IDS!
	A4.	4,851,331	07/25/1989	VARY and DIAMOND	
	A5.	4,965,188	10/23/1990	MULLIS and ERLICH	
	A6.	5,547,835	08/20/1996	KOESTER	
	A7.	5,605,798	02/25/1997	KOESTER	
	A8.	5,679,524	10/21/1997	NIKIFOROV and KARN	
	A9.	5,691,141	11/25/1997	KOESTER	
	A10.	5,834,189	11/10/1998	STEVENS and DUNN	
	A11.	5,849,542	12/15/1998	REEVE and HOWE	
	A12.	5,851,770	12/22/1998	BABON and YOUIL	
	A13.	5,869,242	02/09/1998	KAMB	
	A14.	5,876,934	03/02/1999	DUTHIE and SEVIGNY	
	A15.	5,891,625	04/06/1999	BUCHARDT and EGHOLM	
	A16.	5,908,755	06/01/1999	KUMAR and HEANEY	
	A17.	5,912,118	06/15/1999	ANSORGE and VOSS	
	A18.	5,928,906	07/27/1999	KOESTER and VAN DEN BOOM	
	A19.	5,952,174	09/14/1999	NIKIFOROV and KARN	
	A20.	5,958,692	09/28/1999	COTTON and YOUIL	

EXAMINER

NOT CONSIDERED

DATE CONSIDERED

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

Complete if Known	
Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Sheet 2 of 3

Attorney Docket No: SGL-2020-UT

**US PATENT DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A21.	5,976,802	11/02/1999	ANSORGE and VOSS	
	A22.	5,981,186	11/09/1999	GABE and GILCHRIST	
	A23.	5,998,143	12/07/1999	ELLIS and DODGE	
	A24.	6,004,744	12/21/1999	GOELET and KNAPP	
	A25.	6,013,431	01/11/2000	SOEDERLUND and SYVANEN	
	A26.	6,013,499	01/11/2000	NARUMIYA and IWAMATSU	<i>DUPLICATE REFERENCES</i>
	A27.	6,017,702	01/25/2000	LEE and ROSENBLUM	
	A28.	6,043,031	03/28/2000	KOESTER and HIGGENS	
	A29.	6,046,005	04/04/2000	JU and KONRAD	
	A30.	6,087,095	07/11/2000	ROSENTHAL and BRENNER	
	A31.	6,110,684	08/29/2000	KEMPER and BIRKENKAMP-DEMTRÖDER	
	A32.	6,183,958	02/06/2001	STANTON	
	A33.	6,194,144	02/27/2001	KOESTER	
	A34.	6,210,891	04/03/2001	NYREN and UHLEN	
	A35.	6,229,911	05/08/2001	BALABAN and AGGARWAL	
	A36.				
	A37.				
	A38.				

**FOREIGN PATENT DOCUMENTS**

EXAMINER

*NOT CONSIDERED*

DATE CONSIDERED


Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	09/943,531
		Filing Date	08/30/2001
		First Named Inventor	RISINGER
		Group Art Unit	1634
		Examiner Name	SAKELARIS, SALLY A
Sheet 3 of 3		Attorney Docket No: SGL-2020-UT	

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
A39.	WO0120039		03/22/2001	ROTHBERG and BADER	Not Considered	
A40.	WO0127326		04/19/2001	EGHOLM and CHEN	Duplicate References	
A41.	WO0127327		04/19/2001	BRENNAN and CHATELAIN	from 8/10/05 IDS	
A42.	WO0127329		04/19/2001	MACLEOD and ALDAZ		
A43.						
A44.						

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
A45.	ANDERSON et al., Pharmacogenetics., 2(1):25-31 (1992)		
A46.	BALIAN et al., Clin. Pharmacol. Ther., 57(6):662-669 (1995)	Not Considered IDS	
A47.	BERTILSSON, Clin. Pharmacokinet., 29(3):192-209 (1995)	Duplicated	
A48.	CHANG et al., Br. J. clin. Pharmac., 39:511-518 (1995)	8/10/05	
A49.	EVANS et al., Pharmacogenetics, 5(2):64-71 (1995)		
A50.	GOLDSTEIN et al., Biochemistry, 33(7):1743-1752 (1994)		
A51.	GOLDSTEIN et al., Pharmacogenetics, 7(1):59-64 (1997)		
A52.	GOLDSTEIN, Br. J. clin. Pharmac., 52:349-355 (2001)		
A53.	IBEANU et al., J. Pharmacol. Exp. Ther., 290(2):635-640 (1999)		
A54.	IEIRI et al., Clin. Pharmacol. Ther., 59(6):647-653 (1996)		
A55.	MACAULAY et al., Science, 308:1034-1036 (2005)		
A56.	MEYER and ZANGER, Annu. Rev. Pharmacol. Toxicol., 37:269-296 (1997)		
A57.	RICHARDS et al., Am. J. Hum. Genet. 67:1251-1276 (2000)		
A58.	TANAKA, J Clin Pharm Ther., 24:323-329 (1999)		
A59.	WILKINSON et al., Pharmac. Ther. 43:53-76 (1989)		
A60.	YIN et al., J. Clin. Pharmacol. 44:582-589 (2004)		
A61.			
A62.			

Not Considered**EXAMINER****DATE CONSIDERED**



Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Approved for use through 07/31/2008. GPO: 0-2001-0221 Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.			
		<b>Complete if Known</b>			
		Application Number	09/943,531		
		Filing Date	08/30/2001		
		First Named Inventor	RISINGER		
		Group Art Unit	1634		
Examiner Name	SAKELARIS, SALLY A				
Sheet 1 of 3		Attorney Docket No: SGL-2020-UT			


US PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	4,656,127	04/07/1987	MUNDY	
	A2.	4,683,195	07/28/1987	MULLIS and ERLICH	
	A3.	4,683,202	07/28/1987	MULLIS	
	A4.	4,851,331	07/25/1989	VARY and DIAMOND	
	A5.	4,965,188	10/23/1990	MULLIS and ERLICH	
	A6.	5,547,835	08/20/1996	KOESTER	
	A7.	5,605,798	02/25/1997	KOESTER	
	A8.	5,679,524	10/21/1997	NIKIFOROV and KARN	
	A9.	5,691,141	11/25/1997	KOESTER	
	A10.	5,834,189	11/10/1998	STEVENS and DUNN	
	A11.	5,849,542	12/15/1998	REEVE and HOWE	
	A12.	5,851,770	12/22/1998	BABON and YOUIL	
	A13.	5,869,242	02/09/1998	KAMB	
	A14.	5,876,934	03/02/1999	DUTHIE and SEVIGNY	
	A15.	5,891,625	04/06/1999	BUCHARDT and EGHOLM	
	A16.	5,908,755	06/01/1999	KUMAR and HEANEY	
	A17.	5,912,118	06/15/1999	ANSORGE and VOSS	
	A18.	5,928,906	07/27/1999	KOESTER and VAN DEN BOOM	
	A19.	5,952,174	09/14/1999	NIKIFOROV and KARN	
	A20.	5,958,692	09/28/1999	COTTON and YOUIL	

EXAMINER

DATE CONSIDERED


\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1. Applicant's unique citation designator number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

PTO-1449A (08-03)  
Approved for use through 07/01/2005. GPO: 2003-203-0031-0033  
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Complete if Known	
 <b>AUG 1 0 2005</b> <b>C15</b>		Application Number	09/943,531
		Filing Date	08/30/2001
		First Named Inventor	RISINGER
		Group Art Unit	1634
		Examiner Name	SAKELARIS, SALLY A
Sheet 2 of 3		Attorney Docket No: SGL-2020-UT	

US PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A21.	5,976,802	11/02/1999	ANSORGE and VOSS	
	A22.	5,981,186	11/09/1999	GABE and GILCHRIST	
	A23.	5,998,143	12/07/1999	ELLIS and DODGE	
	A24.	6,004,744	12/21/1999	GOELET and KNAPP	
	A25.	6,013,431	01/11/2000	SOEDERLUND and SYVANEN	
	A26.	6,013,499	01/11/2000	NARUMIYA and IWAMATSU	
	A27.	6,017,702	01/25/2000	LEE and ROSENBLUM	
	A28.	6,043,031	03/28/2000	KOESTER and HIGGINS	
	A29.	6,046,005	04/04/2000	JU and KONRAD	
	A30.	6,087,095	07/11/2000	ROSENTHAL and BRENNER	
	A31.	6,110,684	08/29/2000	KEMPER and BIRKENKAMP-DEMTRÖDER	
	A32.	6,183,958	02/06/2001	STANTON	
	A33.	6,194,144	02/27/2001	KOESTER	
	A34.	6,210,891	04/03/2001	NYREN and UHLEN	
	A35.	6,229,911	05/08/2001	BALABAN and AGGARWAL	
	A36.				
	A37.				
	A38.				

#### FOREIGN PATENT DOCUMENTS

EXAMINER 

DATE CONSIDERED 9/22/05

Substitute Disclosure Statement Form (PTO-1449)

<sup>1</sup> EXAMINER: Initials referenced considered, whether or not disclosure is in conformance with MPEP 600. Draw line through disclosure if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique identification designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

AUG 10 2005

Sheet 3 of 3

U.S. PATENT AND TRADEMARK OFFICE

PTO-1449A (3-07) Approved for use through 07/31/2005. GPO: 0501-003  
 U.S. Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Attorney Docket No: SGL-2020-UT

Examiner Initials*	Cite No.*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
SA	A39.	WO0120039	03/22/2001	ROTHBERG and BADER		
	A40.	WO0127326	04/19/2001	EGHOLM and CHEN		
	A41.	WO0127327	04/19/2001	BRENNAN and CHATELAIN		
SA	A42.	WO0127329	04/19/2001	MACLEOD and ALDAZ		
	A43.					
	A44.					

**OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SA	A45.	ANDERSON et al., Pharmacogenetics., 2(1):25-31 (1992)	
	A46.	BALIAN et al., Clin. Pharmacol. Ther., 57(6):662-669 (1995)	
	A47.	BERTILSSON, Clin. Pharmacokinet., 29(3):192-209 (1995)	
	A48.	CHANG et al., Br. J. clin. Pharmac., 39:511-518 (1995)	
	A49.	EVANS et al., Pharmacogenetics, 5(2):64-71 (1995)	
	A50.	GOLDSTEIN et al., Biochemistry, 33(7):1743-1752 (1994)	
	A51.	GOLDSTEIN et al., Pharmacogenetics, 7(1):59-64 (1997)	
	A52.	GOLDSTEIN, Br. J. clin. Pharmac., 52:349-355 (2001)	
	A53.	IBEANU et al., J. Pharmacol. Exp. Ther., 290(2):635-640 (1999)	
	A54.	IEIRI et al., Clin. Pharmacol. Ther., 59(6):647-653 (1996)	
	A55.	MACAULAY et al., Science, 308:1034-1036 (2005)	
	A56.	MEYER and ZANGER, Annu. Rev. Pharmacol. Toxicol., 37:269-296 (1997)	
	A57.	RICHARDS et al., Am. J. Hum. Genet. 67:1251-1276 (2000)	
	A58.	TANAKA, J Clin Pharm Ther., 24:323-329 (1999)	
SA	A59.	WILKINSON et al., Pharmac. Ther. 43:53-76 (1989)	
	A60.	YIN et al., J. Clin. Pharmacol. 44:582-589 (2004)	
	A61.		
	A62.		

EXAMINER


*Sally A. Sakelaris*

DATE CONSIDERED

9/22/05

Substitute Disclosure Statement Form (PTO-1449)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional) \*Applicant is to place a check mark here if English language Translation is attached



Approved for use through 07/31/2005 GPO: 05-100-0001  
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(use as many sheets as necessary)</small>		<b>Complete if Known</b>	
		Application Number	09/943,531
		Filing Date	08/30/2001
		First Named Inventor	RISINGER
		Group Art Unit	1634
		Examiner Name	SAKELARIS, SALLY A
Sheet 1 of 3		Attorney Docket No: SGL-2020-UT	

US PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	4,656,127	04/07/1987	MUNDY	
	A2.	4,683,195	07/28/1987	MULLIS and ERLICH	
	A3.	4,683,202	07/28/1987	MULLIS	
	A4.	4,851,331	07/25/1989	VARY and DIAMOND	
	A5.	4,965,188	10/23/1990	MULLIS and ERLICH	
	A6.	5,547,835	08/20/1996	KOESTER	
	A7.	5,605,798	02/25/1997	KOESTER	
	A8.	5,679,524	10/21/1997	NIKIFOROV and KARN	
	A9.	5,691,141	11/25/1997	KOESTER	
	A10.	5,834,189	11/10/1998	STEVENS and DUNN	
	A11.	5,849,542	12/15/1998	REEVE and HOWE	
	A12.	5,851,770	12/22/1998	BABON and YOUIL	
	A13.	5,869,242	02/09/1998	KAMB	
	A14.	5,876,934	03/02/1999	DUTHIE and SEVIGNY	
	A15.	5,891,625	04/06/1999	BUCHARDT and EGHOLM	
	A16.	5,908,755	06/01/1999	KUMAR and HEANEY	
	A17.	5,912,118	06/15/1999	ANSORGE and VOSS	
	A18.	5,928,906	07/27/1999	KOESTER and VAN DEN BOOM	
	A19.	5,952,174	09/14/1999	NIKIFOROV and KARN	
	A20.	5,958,692	09/28/1999	COTTON and YOUIL	

EXAMINER

DATE CONSIDERED

9/22/05

Information Disclosure Statement Form (PTO-1449)  
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1. Applicant's unique citation designation number (optional) 2. Applicant is to place a check mark here if English language Translation is attached

PTO-946 (04-02)  
Approved for use through 07/31/2005. GPO: 2003-1-0201  
U.S. Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(Use as many sheets as necessary)</small>		<b>Complete if Known</b>	
		<b>Application Number</b>	09/943,531
		<b>Filing Date</b>	08/30/2001
		<b>First Named Inventor</b>	RISINGER
		<b>Group Art Unit</b>	1634
		<b>Examiner Name</b>	SAKELARIS, SALLY A
Sheet 2 of 2			
Attorney Docket No: SGL-2020-UT			

US PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A21.	5,976,802	11/02/1999	ANSORGE and VOSS	
	A22.	5,981,186	11/09/1999	GABE and GILCHRIST	
	A23.	5,998,143	12/07/1999	ELLIS and DODGE	
	A24.	6,004,744	12/21/1999	GOELET and KNAPP	
	A25.	6,013,431	01/11/2000	SOEDERLUND and SYVANEN	
	A26.	6,013,499	01/11/2000	NARUMIYA and IWAMATSU	
	A27.	6,017,702	01/25/2000	LEE and ROSENBLUM	
	A28.	6,043,031	03/28/2000	KOESTER and HIGGENS	
	A29.	6,046,005	04/04/2000	JU and KONRAD	
	A30.	6,087,095	07/11/2000	ROSENTHAL and BRENNER	
	A31.	6,110,684	08/29/2000	KEMPER and BIRKENKAMP-DEMTRÖDER	
	A32.	6,183,958	02/06/2001	STANTON	
	A33.	6,194,144	02/27/2001	KOESTER	
	A34.	6,210,891	04/03/2001	NYREN and UHLEN	
	A35.	6,229,911	05/08/2001	BALABAN and AGGARWAL	
	A36.				
	A37.				
	A38.				

#### FOREIGN PATENT DOCUMENTS

EXAMINER

DATE CONSIDERED

*Sally A. Sakelaris* 9/22/05

Substitute Disclosure Statement Form (PTO-1449)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique identification designation number (optional): Applicant is to place a check mark here if English language Translation is attached.

<p>Substitute for Form 1440A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)</p> <p style="text-align: center;">AUG 10 2005 SAC</p>		<b>Complete if Known</b>	
		Application Number	09/943,531
		Filing Date	08/30/2001
		First Named Inventor	RISINGER
		Group Art Unit	1634
		Examiner Name	SAKELARIS, SALLY A
Sheet 3 of 3 U.S. TRADEMARK OFFICE			
Attorney Docket No: SGL-2020-UT			

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
SP	A39.	WO0120039	03/22/2001	ROTHBERG and BADER		
SP	A40.	WO0127326	04/19/2001	EGHOLM and CHEN		
SP	A41.		04/19/2001	BRENNAN and CHATELAIN		
SP	A42.	WO0127327	04/19/2001	MACLEOD and ALDAZ		
SP	A43.	WO0127329				
SP	A44.					

#### OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SP	A45.	ANDERSON et al., Pharmacogenetics., 2(1):25-31 (1992)	
SP	A46.	BALIAN et al., Clin. Pharmacol. Ther., 57(6):682-689 (1995)	
SP	A47.	BERTILSSON, Clin. Pharmacokinet., 29(3):192-209 (1995)	
SP	A48.	CHANG et al., Br. J. clin. Pharmac., 39:511-518 (1995)	
SP	A49.	EVANS et al., Pharmacogenetics, 5(2):64-71 (1995)	
SP	A50.	GOLDSTEIN et al., Biochemistry, 33(7):1743-1752 (1994)	
SP	A51.	GOLDSTEIN et al., Pharmacogenetics, 7(1):59-64 (1997)	
SP	A52.	GOLDSTEIN, Br. J. clin. Pharmac., 52:349-355 (2001)	
SP	A53.	IBEANU et al., J. Pharmacol. Exp. Ther., 290(2):635-640 (1999)	
SP	A54.	IEIRI et al., Clin. Pharmacol. Ther., 59(6):647-653 (1996)	
SP	A55.	MACAULAY et al., Science, 308:1034-1036 (2005)	
SP	A56.	MEYER and ZANGER, Annu. Rev. Pharmacol. Toxicol., 37:269-296 (1997)	
SP	A57.	RICHARDS et al, Am. J. Hum. Genet. 67:1251-1278 (2000)	
SP	A58.	TANAKA, J Clin Pharm Ther., 24:323-329 (1999)	
SP	A59.	WILKINSON et al., Pharmac. Ther. 43:53-78 (1989)	
SP	A60.	YIN et al., J. Clin. Pharmacol. 44:582-589 (2004)	
SP	A61.		
SP	A62.		

EXAMINER

DATE CONSIDERED

9/22/05

Substitute Disclosure Statement Form (PTO-1440)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to  
Applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached